Regeneron (REGN) Tops Q3 EPS by 69c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Regeneron Pharma (REGN) PT Raised to $315 at Barclays
November 7, 2018 7:34 AM ESTBarclays analyst Geoff Meacham raised the price target on Regeneron Pharma (NASDAQ: REGN) to $315.00 (from $305.00) while maintaining a Underweight rating following the company's 3Q earnings report.
Meacham thought Regenerons 3Q results were very good (+$22M top-line; +$0.70 bottom-line), and while Barclays continues to... More
